Q1 EPS Forecast for Allogene Therapeutics Lifted by Analyst

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for Allogene Therapeutics in a research report issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.27) per share for the quarter, up from their previous forecast of ($0.29). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.14) EPS.

ALLO has been the subject of several other research reports. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research report on Friday, March 14th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Allogene Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $9.29.

Allogene Therapeutics Stock Down 0.6 %

Allogene Therapeutics stock opened at $1.62 on Friday. Allogene Therapeutics has a twelve month low of $1.32 and a twelve month high of $4.63. The company’s 50-day moving average price is $1.89 and its 200-day moving average price is $2.28. The company has a market cap of $351.97 million, a PE ratio of -1.04 and a beta of 1.02.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06.

Hedge Funds Weigh In On Allogene Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ALLO. Lynx1 Capital Management LP raised its position in Allogene Therapeutics by 75.3% during the fourth quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company’s stock valued at $23,163,000 after acquiring an additional 4,672,349 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Allogene Therapeutics by 30.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company’s stock valued at $7,586,000 after purchasing an additional 831,146 shares in the last quarter. Foresite Capital Management VI LLC purchased a new position in shares of Allogene Therapeutics during the 4th quarter valued at approximately $7,345,000. Geode Capital Management LLC lifted its stake in shares of Allogene Therapeutics by 14.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after purchasing an additional 407,070 shares during the period. Finally, Two Sigma Advisers LP boosted its holdings in Allogene Therapeutics by 12.1% during the fourth quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company’s stock worth $5,756,000 after buying an additional 291,800 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Insider Activity

In other news, CEO David D. Chang sold 46,668 shares of the company’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the sale, the chief executive officer now directly owns 5,276,569 shares of the company’s stock, valued at $10,342,075.24. This represents a 0.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Zachary Roberts sold 27,199 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now directly owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. This trade represents a 5.28 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 104,866 shares of company stock valued at $194,461. Company insiders own 24.30% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).